Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Suzhou Connect Biopharmaceuticals

8 clinical trials

Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
Status: Completed, Estimated PCD: 2023-08-05
Clinical trial
A Double-blind, Multi-center, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of CBP-201 in Chinese Subjects With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Randomized, Open-Label, Parallel-Designed, Phase I Clinical Study to Evaluate the Pharmacokinetics Similarity of Single-Dose CBP-201 Injection With Different Dosage Forms and Strengths in Healthy Adult Chinese Subjects
Status: Completed, Estimated PCD: 2023-10-06
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Withdrawn, Estimated PCD: 2024-08-01
Clinical trial
A Multi-Center, Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate CBP-201 in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
Status: Terminated, Estimated PCD: 2022-04-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2021-07-28
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Status: Completed, Estimated PCD: 2022-02-23